Article citationsMore>>
Green, N.K., Morrison, J., Hale, S., Briggs, S.S., Stevenson, M., Subr, V., Ulbrich, K., Chandler, L., Mautner, V., Seymour, L.W. and Fisher, K.D. (2008) Retargeting Polymer-Coated Adenovirus to the FGF Receptor Allows Productive Infection and Mediates Efficacy in a Peritoneal Model of Human Ovarian Cancer. The Journal of Gene Medicine, 10, 280-289. http://dx.doi.org/10.1002/jgm.1121
has been cited by the following article:
-
TITLE:
Oncoselectivity in Oncolytic Viruses against Colorectal Cancer
AUTHORS:
Steven J. Conrad, Karim Essani
KEYWORDS:
Colorectal Cancer, Replication-Competent Oncolytic Virus, Oncoselectivity, Virotherapy
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.5 No.13,
November
6,
2014
ABSTRACT:
In humans colorectal cancer (CRC) is a
significant cause of morbidity and mortality. New treatment options are
urgently needed to supplement existing therapies. Replication-competent
oncolytic viruses (RCOVs) for the treatment of cancerous tumorsin vivois a relatively new
therapeutic modality with great but largely unrealized potential against CRC.
In the context of oncolytic virus safety, oncoselectivity is an important
criterion. It is at the conceptual intersection of viral replication strategy
and tumor cell biology that RCOVs acquire their oncoselectivity, and thus their
safety. Every aspect of tumor molecular biology which distinguishes it from
normal, non-neoplastic cells is a potential target for exploitation. In the
first section of this review we will provide an explanation of some of the
successful and widely used strategies for improving oncoselectivity in
wild-type viruses to make them more suitable as RCOVs. In the second section we
will describe some of the characteristics of CRC biology which can be exploited
to provide oncoselectivity against CRC. Throughout the review examples of
successfully-engineered RCOVs which embody the approach or strategy under
discussion are noted. By showing what has been done, we hope to highlight what
is possible and what remains to be done to generate oncoselective RCOVs for use
against CRC in humans.
Related Articles:
-
Rawia Eljaili Elmassry, Aisha Osman Mohammed, Amina Ibrahim Badawy, Rasha Saad Abdalhamid, Huda Abdalla Eltahir, Safa Abass Mohammed, Hammad Yahia Abdou, Adil Abdelrahim Yousif, Zubaida Abohumeda Adam, Nazik Elmalaika Husaim
-
Stine Lohmann, Anna Krarup Keller
-
Xiaolian Liao, Shangzhao Li, Guohua Chen
-
Arezo Shahi, Naghmeh Bahrami, Atefeh Fakharian, Somayeh Sharifynia, Elham Moslemi, Amir Izadi, Adnan Khosravi, Hamidreza Jamaati, Abdolreza Mohamadnia
-
Ahmed Abdel-Azeem Essmat, Mahmoud El-Sayed Meleis, Helmy Abdel-Sattar Rady, Inass Ibrahim Ahmed Zaki, Ahmed Shaaban Ali Ragab Khattab